Using Alginate Oligosaccharides to Help Nanoparticles Move Through Cystic Fibrosis Mucus
Author Information
Author(s): R. Maeshima, A. D. Tagalakis, D. Gyftaki‐Venieri, S. A. Jones, P. D. Rye, A. Tøndervik, O. A. H. Åstrand, S. L. Hart
Primary Institution: UCL Great Ormond Street Institute of Child Health
Hypothesis
Can low molecular weight alginate oligosaccharides enhance the diffusion of cationic nanoparticles through cystic fibrosis mucus?
Conclusion
Low molecular weight alginate oligosaccharides improve the mucus penetration of cationic nanoparticles, offering a promising alternative to PEGylation for delivering genetic therapies.
Supporting Evidence
- Alginate oligosaccharides enhance the mucus diffusion rates of cationic siRNA and mRNA RTNs.
- OligoG was particularly effective in improving diffusion rates.
- PEGylation improved diffusion rates of siRNA RTNs but not mRNA RTNs.
- RTNs remained intact after mucosal transit.
- OligoM-coated mRNA RTNs showed better transfection efficiency than those coated with OligoG or PEG.
Takeaway
This study found that special sugars called alginate oligosaccharides can help tiny particles move through thick mucus in people with cystic fibrosis, making it easier to deliver medicine.
Methodology
The study used a static mucus barrier diffusion model to test the diffusion rates of cationic nanoparticles coated with alginate oligosaccharides.
Limitations
The study primarily focused on in vitro models, which may not fully replicate in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website